Kimberly-Clark Corporation (KMB) Income Statement

The reported revenue decline of 14.2% in 2026Q1 and 17.2% in 2025Q4 likely stems from exiting low-margin tissue businesses in international markets, as indicated by the company's segment disclosures. This portfolio pruning appears to be a deliberate strategy to improve margin quality, but it reduces scale and may limit future top-line growth. Investors should monitor whether organic sales, which exclude divestitures and currency, can sustain positive momentum, as the underlying consumer demand for hygiene products remains defensive.

The gross margin expansion of 330 basis points year-over-year is notable given the commodity-linked cost structure, implying that management's pricing actions and product mix improvements are offsetting pulp and resin cost increases. However, the 35.6% gross margin remains below peers like PG (50.2%) and CHD (44.7%), reflecting the structural ceiling of tissue products. The sustainability of this margin improvement depends on the lagged pass-through of input costs, which may compress margins in coming quarters if pulp prices rise further.

The 350 basis point decline in operating margin is driven by a disproportionate increase in SG&A expenses, which rose from $863 million to $1.0 billion, while gross profit only grew modestly. This suggests that overhead costs are not being managed efficiently relative to the revenue base, possibly due to investments in brand support or supply chain modernization. The elevated SG&A ratio may indicate that the company is spending to defend market share, but it is eroding profitability and warrants monitoring for cost discipline.

The reduction in COGS ratio indicates successful cost-saving initiatives and favorable input cost timing, but the increase in SG&A to 23.8% of revenue from 20.5% a year ago is concerning. This rise may reflect higher marketing spend to support brand momentum or increased logistics costs, but it is consuming the gross margin improvements. Management's expense discipline appears to be wavering, and investors should monitor whether SG&A can be reined in to protect operating margins.

The 2024Q3 results stand out with operating income of $1.0 billion and net income of $907 million, far exceeding any other quarter in the dataset. This appears to be a non-recurring event, likely a gain from divestitures or a tax benefit, as margins reverted to the mid-teens in subsequent quarters. The lasting impact is that investors should not extrapolate from that quarter's profitability, and the company's underlying operating margin is closer to 11-12%, which is below historical averages and peers.